The method of lines solution of time-dependent 2D navier-stokes equations for incompressible separated internal flows

Ph.D. - Doctoral Progra

Linyitle yakılan akışkan yataklı yakıcılarda azot oksit (NOx) emisyonlarının belirlenmesi

TÜBİTAK MİSAG02.02.1998Bu çalışmada ODTÜ Kimya Mühendisliği Bölümü'nde kumlu olan 0.3 MW ısıl güçteki akışkan yataklı yakıcı üzerinde tipik bir Türk linyitini temsil eden kül, uçucu madde ve kükürt içeriği kaliteli kömürlere göre yüksek olan Beypazarı linyitinin yakılmasıyla ortaya çıkan NOX ve diğer baca gazlarının $(CO_2, CO, O_2 ve SO_2)$ emisyonları on-line ölçümlerle belirlenmiştir. NOx'in yakıcı boyunca dağılımının ve baca gazındaki emisyonunun fazla hava ve kireçtaşı katkısı ile değişimi incelenmiştir. Bulgular, NOx'in daha ziyade linyitin uçucu madde içeriğinden kaynaklandığını ve bu nedenle NOX oluşumunun çalışılan sıcaklık aralığında (857-918°C) sıcaklıktan etkilenmediğini göstermiştir. Baca gazındaki NOX emisyonunun hava fazlasıyla arttığı, kireçtaşı katkısıyla da azaldığı tesbit edilmiştir. Ölçümlerle belirlenen baca gazı emisyonları, günümüzdeki ulusal ve uluslararası standart aralıklarıyla karşılaştırılmış ve izin verilebilir değerlerin altında kaldığı görülmüştür

Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study

Objective: This study aimed to evaluate systemic thrombolysis experiences with recombinant tissue plasminogen activator (rtPA). Materials and Methods: Retrospective data were collected from 13 Turkish pediatric hematology centers. The dose and duration of rtPA treatment, concomitant anticoagulant treatment, complete clot resolution (CCR), partial clot resolution (PCR), and bleeding complications were evaluated. Low-dose (LD) rtPA treatment was defined as 0.01-0.06 mg/kg/h and high-dose (HD) rtPA as 0.1-0.5 mg/kg/h. Results: Between 2005 and 2019, 55 thrombotic episodes of 54 pediatric patients with a median age of 5 years (range: 1 day to 17.75 years) were evaluated. These patients had intracardiac thrombosis (n=16), deep vein thrombosis (DVT) (n=15), non-stroke arterial thrombosis (n=14), pulmonary thromboembolism (PE) (n=6), and stroke (n=4). The duration from thrombus detection to rtPA initiation was a median of 12 h (range: 2-504 h) and it was significantly longer in cases of DVT and PE compared to stroke, non-stroke arterial thrombosis, and intracardiac thrombosis (p=0.024). In 63.6% of the episodes, heparin was initiated before rtPA treatment. LD and HD rtPA were administered in 22 and 33 of the episodes, respectively. Concomitant anticoagulation was used in 90% and 36% of the episodes with LD and HD rtPA, respectively (p=0.0001). Median total duration of LD and HD rtPA infusions was 30 h (range: 2-120 h) and 18 h (2-120 h), respectively (p=0.044). Non-fatal major and minor bleeding rates were 12.5% and 16.7% for LD and 3.2% and 25.8% for HD rtPA, respectively. At the end of the rtPA infusions, CCR and PCR were achieved in 32.7% and 49.0% of the episodes, respectively. The most successful site for thrombolysis was intracardiac thrombosis. HD versus LD rtPA administration was not correlated with CCR/PCR or bleeding (p>0.05). Conclusion: Systemic thrombolytic therapy may save lives and organs effectively if it is used at the right indications and the right times in children with high-risk thrombosis by experienced hematologists with close monitoring of recanalization and bleeding

TURKISH NATIONAL SEVERE CONGENITAL NEUTROPENIA REGISTRY

WOS: 000440320200028TUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); Turkish Pediatric Hematology AssociationThis study was supported by TUBITAK and Turkish Pediatric Hematology Association

Turkish National Severe Congenital Neutropenia Registry

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) -- DEC 03-06, 2016 -- San Diego, CAWOS: 000394452701110Amer Soc HematolTUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)Yilmaz Karapinar: TUBITAK: Research Funding

Homozygous c.130-131 ins A (pW44X) mutation in the HAX1 gene as the most common cause of congenital neutropenia in Turkey: Report from the Turkish Severe Congenital Neutropenia Registry

Background Severe congenital neutropenia is a rare disease, and autosomal dominantly inherited ELANE mutation is the most frequently observed genetic defect in the registries from North America and Western Europe. However, in eastern countries where consanguineous marriages are common, autosomal recessive forms might be more frequent. Method Two hundred and sixteen patients with severe congenital neutropenia from 28 different pediatric centers in Turkey were registered. Results The most frequently observed mutation was HAX1 mutation (n = 78, 36.1%). A heterozygous ELANE mutation was detected in 29 patients (13.4%) in our cohort. Biallelic mutations of G6PC3 (n = 9, 4.3%), CSF3R (n = 6, 2.9%), and JAGN1 (n = 2, 1%) were also observed. Granulocyte colony-stimulating factor treatment was given to 174 patients (80.6%). Two patients died with infectious complications, and five patients developed myelodysplastic syndrome/acute myeloblastic leukemia. The mean (+/- mean standard error) follow-up period was 129.7 +/- 76.3 months, and overall survival was 96.8% (CI, 94.4-99.1%) at the age of 15 years. In Turkey, severe congenital neutropenia mostly resulted from the p W44X mutation in the HAX1 gene. Conclusion In Turkey, mutation analysis should be started with HAX1, and if this is negative, ELANE and G6PC3 should be checked. Because of the very high percentage of consanguineous marriage, rare mutations should be tested in patients with a negative mutation screen